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Abstract: The ketogenic diet (KD) is increasingly used to treat epilepsy refractory to antiepileptic
drugs and other neurological disorders. In animal models, the KD was found to increase the
threshold to seizures induced by different convulsive stimulations. However, in models in which
suprathreshold stimuli were used, a paradoxical seizure worsening was consistently observed in
KD-fed animals. To better define this phenomenon, we characterized the electrographic response to
seizures induced in mice which were treated with the KD, and then corneally stimulated at 6-Hz in
four different sessions. We also evaluated the electroencephalogram (EEG) in three patients in which
the KD was associated with a paradoxical worsening of epileptic seizures. Although seizures were
initially less severe, a remarkable prolongation of the electrographic response was observed in mice
receiving the KD from the second session of 6-Hz corneal stimulation and onwards. The EEG was
also markedly altered in the presence of progressive seizure aggravation observed in children treated
with the KD, specifically one affected by Lennox–Gastaut syndrome and two by type I lissencephaly.
These results suggest that when seizures are induced or recur because of resistance to therapeutic
interventions, the KD may change the EEG by potentiating the electrographic epileptic activity.
Keywords: 6-Hz corneal stimulation; electroencephalography; ketogenic diet; Lennox-Gastaut
syndrome; lissencephaly; seizure
1. Introduction
Epilepsy affects approximately 70 million patients worldwide [1]. Although a variety of
antiepileptic drugs (AEDs) are currently available to address this neurological disorder, up to one-third
of people affected by epilepsy do not properly respond to AEDs and present increased risk of premature
death [2]. This major neurological problem may be partly addressed by treating patients who are
refractory to AEDs with a ketogenic diet (KD) [3]. This nutritional approach has been proved to be
effective in most drug-resistant pediatric patients [4] and, according to a recent meta-analysis [5],
reduction in seizure frequency is observed in the vast majority of children maintained on a typical KD
for at least three months. Additionally, the KD is used as a first line intervention in patients affected
by GLUT-1 deficiency syndrome and pyruvate dehydrogenase complex deficiency (PDCD), who
experience difficult-to-treat seizures because of reduced glucose transport or metabolism [5]. Moreover,
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ketone bodies have been considered as a tool to address the reduced glucose uptake occurring in the
brain of patients affected by Alzheimer’s disease [6].
In spite of the recognized efficacy of the KD, the clinical use of this nutritional approach is not
so widespread as could be expected [7]. One of the reasons for this limited use could be found in
the considerable high dropout rates reported in patients maintained on the KD [8]. In addition,
adverse events may also be encountered during the initiation period of the KD, the most frequent
of which are represented by gastrointestinal disorders, reported to occur in one-third or more of the
treated children [9]. Occasionally, kidney stones and metabolic disorders may also occur during KD
administration. A further reason for dropping out of the KD could be the lack of positive response to
the treatment, a phenomenon which is especially encountered in the long-term [8]. On the other hand,
dropouts due to increased seizure frequency or severity have not been reported in patients maintained
on the KD [8], although paradoxical seizure worsening is instead observed in patients affected by
epilepsy and treated with AEDs [10].
A different scenario emerged from studies based on animal models. Although the KD has been
consistently shown to increase the threshold of seizure induction, lack of effects or paradoxical seizure
worsening were instead reported when suprathreshold stimuli were applied [11–14]. The variability
found in animal models has tentatively been explained by considering the specific protocol used
to induce the seizures when testing the KD effects [14]. For instance, seizures were more severe in
rodents maintained on the KD and exposed to kainate-induced status epilepticus or to a maximal
electroshock [14,15], whereas the KD was consistently found to be protective in the 6-Hz corneal
stimulation test [16,17]. As this latter test is thought to model seizures refractory to AEDs [18–20],
it appears particularly interesting that the KD may increase the threshold to 6-Hz corneally
induced seizures.
In view of the positive results obtained by investigating the KD in two different kindling models,
as well as in the pilocarpine model [21,22], a further possible therapeutic application of this nutritional
treatment has been suggested for epileptogenesis. However, when performing similar experiments,
other investigators observed partial effects [23] or no results [24]. As we recently proposed a model of
repeated 6-Hz corneal stimulation in which seizures were found to progressively increase in severity,
so to prefigure an epileptogenic process [25–27], we aimed at evaluating the KD effects in this model.
Specifically, we decided to carefully monitor the KD effects on the progression in seizure severity
caused by repeating the seizure induction, as well as to assess the KD effects on electrographic
discharges recorded from mice exposed to the four different sessions of 6-Hz corneal stimulation.
Additionally, we retrospectively examined patients maintained on the KD to evaluate whether the
observations made in the animal model could be clinically relevant.
2. Results
2.1. Seizure Worsening after an Initial Beneficial Effect of KD Administration in Mice
Mice maintained on the KD developed a significant ketosis, as β-hydroxybutyric acid levels
increased three-fold (1.7± 0.1 mmol/mL, mean± standard error of the mean (SEM); p < 0.01, Student’s
t test) with respect to controls (0.5 ± 0.05 mmol/mL). By visual inspection, the first seizure induced
by 6-Hz stimulation was shorter in KD-treated mice compared to control mice (114.7 ± 15.1 vs.
211.2 ± 31.7 s; p < 0.001, Holm–Šídák test; Figure 1a). However, no differences in duration were
found between the two groups in the following session because seizures shortened significantly in
controls (113.9 ± 16.4 s in session 2, p < 0.001 vs. session 1 of control group), as expected [25–27].
Consistently, the change in seizure duration was caused by the shortening of the non-motor component
of the seizure, corresponding to stunned behavior, whereas the motor component did not change
in both groups (Figure 1b,c). More importantly, the seizure severity, evaluated as the percentage of
animals presenting generalized tonic-clonic convulsions with postural loss, was significantly higher in
control mice (56% compared to 20% in mice fed the KD; p < 0.05, Fisher’s exact test) during the first
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seizure (Figure 1d). Again, no differences were found in the other sessions as an increasing number
of mice under KD developed generalized tonic-clonic convulsions. None of the animals developed
spontaneous seizures and no seizure was observed in the interstimulation period or even after the four
sessions of seizure induction.
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Figure 1. Behavioral changes during repeated 6-Hz corneal stimulation in mice fed the ketogenic diet 
(KD). (a) Seizure duration, considered as the overall period including both motor (convulsions) and 
non-motor (stunned posture) components of the seizure, was significantly shorter in KD vs. control 
mice at the first session (*** p < 0.001; Holm–Šídák test); however, after the first session the seizure 
duration decreased in control mice (### p < 0.001 for sessions 2, 3 and 4 vs. session 1) and no 
differences were observed between the two groups. (b) Histograms illustrating the mean duration of 
the motor component of the seizure. Note that no differences were found between the two treatment 
groups. (c) Histograms illustrating the mean duration of the non-motor component of the seizure, 
which was significantly shorter in KD vs. control mice only at the first session of corneal stimulation 
(*** p < 0.001). Note that this component decreased in control mice from the second to the last session 
(### p < 0.001 vs. session 1). For this reason, no treatment-related differences were observed in 
sessions 2–4. (d) Note that the KD significantly reduced the number of animals developing 
generalized tonic-clonic convulsions with postural loss at the first seizure induction (* p < 0.05, 
Fisher’s exact test). However, this difference was not appreciated in further sessions; n = 9 for the 
normal diet (ND) group; n = 9 for KD group. Statistical significance values are indicated as *: p < 0.05, 
***: p < 0.001, ###: p < 0.001. 
By analyzing the electrocorticographic (ECoG) traces (Figure 2a), apparently similar 
epileptiform events were recorded in the first session. As previously described [25], an ictal 
component followed by post-ictal flattening of the activity was found in both groups (Figure 3). Ictal 
activity lasted for a similar time interval in the two groups (Figure 2b), whereas the post-ictal 
depression was initially shorter in the KD group (p < 0.01, Holm–Šídák test; Figures 2c and 3). 
Confirming our previous results [25], in the second session the period of post-ictal flattening was 
shortened in control mice maintained on the normal diet (ND) (p < 0.01 vs. session 1 of control group; 
Figure 2c), whereas no changes were present in mice maintained on the KD. Surprisingly, in the 
ECoG of mice fed the KD (Figure 2a) the ictal component of the electrographic seizure appeared to 
be more persistent in the second session compared to the first session (p < 0.01) (Figure 2b). This 
change was significant also when compared to values measured in control mice during the second 
session (p < 0.01; Figure 2b). Interestingly, a longer ictal activity was observed in the KD group in the 
Figure 1. Behavioral changes during repeated 6-Hz corneal stimulation in mice fed the ketogenic
diet (KD). (a) Seizure duration, considered as the overall period including both motor (convulsions)
and non-motor (stunned posture) components of the seizure, was significantly shorter in KD vs. control
mice at the first session (*** p < 0.001; Holm–Šídák test); however, after the first session the seizure
duration decreased in control mice (### p < 0.001 for sessions 2, 3 and 4 vs. session 1) and no differences
were observed between the two groups. (b) Histograms illustrating the mean duration of the motor
component of the seizure. Note that no differences were found between the two treatment groups.
(c) Histograms illustrating the mean duration of the non-motor component of the seizure, which was
significantly shorter in KD vs. control mice only at the first session of corneal stimulation (*** p < 0.001).
Note that this component decreased in control mice from the second to the last session (### p < 0.001 vs.
session 1). For this reason, no treatment-related differences were observed in sessions 2–4. (d) Note that
the KD significantly reduced the number of animals developing generalized tonic-clonic convulsions
with postural loss at the first seizure in uctio (* p < 0.05, Fisher’s exact test). However, this difference
was t appreciated in f rther sessions; n = 9 for the normal diet (ND) group; n = 9 for KD group.
Statistical significance values are indicated as *: p < 0.05, ***: p < 0.001, ###: p < 0.001.
By analyzing the electrocorticographic (ECoG) traces (Figure 2a), apparently similar epileptiform
events were recorded in the first session. As previously described [25], an ictal component followed by
post-ictal flattening of the activity was found in both groups (Figure 3). Ictal activity lasted for a similar
time interval in the two groups (Figure 2b), whereas the post-ictal depression was initially shorter in
the KD group (p < 0.01, Holm–Šídák test; Figures 2c and 3). Confirming our previous results [25], in
the second session the period of post-ictal flattening was shortened in control mice maintained on
the normal diet (ND) (p < 0.01 vs. session 1 of control group; Figure 2c), whereas no changes were
present in mice maintained on the KD. Surprisingly, in the ECoG of mice fed the KD (Figure 2a) the
ictal co ponent of the electrographic seizure appeared to be more persistent in the second session
compared to the first session (p < 0.01) (Figure 2b). This change was significant also when compared
to values measured in control mice during the second session (p < 0.01; Figure 2b). Interestingly,
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a longer ictal activity was observed in the KD group in the further sessions of seizure induction, being
significantly longer in the fourth compared to the first session of seizure induction in the same animals
(p < 0.05; Figure 2b).
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Figure 2. Video electrocorticographic (ECoG) recordings in mice fed the ketogenic diet (KD) and 
repeatedly tested in the 6-Hz corneal stimulation model. (a) EcoG traces illustrating the response 
detected in the presence of the normal diet (ND) or the KD, during and after a corneal stimulation of 
one representative mouse after repeated electrostimulations. The black bar indicates a stimulus 
artifact. Black arrows indicate the end of the ictal discharge. Note that the epileptiform activity 
changed in terms of duration and waveform when comparing session 1 with session 2. (b) 
Histograms illustrating the mean duration of ictal discharges recorded in session 1 and 2 in ND (n = 
9) and KD (n = 9) groups. The duration of ictal discharges significantly increased in KD mice at the 
second session of stimulation (## p < 0.01 for session 2 vs. session 1; Holm–Šídák test). Moreover, 
these values were significantly higher than in ND mice when considering session 2 (** p < 0.01). 
Interestingly, a longer ictal activity was observed in the KD group in the subsequent sessions of 
seizure induction. In particular, a statistical difference was found by comparing session 4 to session 1 
in the same animals (# p < 0.05; Holm–Šídák test). (c) Histograms illustrating the mean duration of 
post-ictal depression as measured in the various sessions of 6-Hz corneal stimulation. The duration 
of post-ictal depression was significantly reduced in the ND group at the second session of 
stimulation (## p < 0.01, sessions 2 vs. session 1). Note also that at the first session, post-ictal 
depression was shorter in KD mice compared to ND mice (** p < 0.01). RFC denotes right frontal 
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Figure 2. Video electrocorticographic (ECoG) recordings in mice fed the ketogenic diet (KD) and
repeatedly tested in the 6-Hz corneal stimulation model. (a) ECoG traces illustrating the response
detected in the presence of the normal diet (ND) or the KD, during and after a corneal stimulation of
one representative mouse after repeated electrostimulations. The black bar indicates a stimulus artifact.
Black arrows indicate the end of the ictal discharge. Note that the epileptiform activity changed in
terms of duration and waveform when comparing session 1 with session 2. (b) Histograms illustrating
the mean uration of ictal discharges recorded in session 1 and 2 in ND (n = 9) and KD (n = 9) groups.
The duration of ictal di charges significantly inc ea ed in KD mice at the second session of stimulation
(## p < 0.01 for session 2 vs. session 1; Holm–Šídák test). Moreover, th se values were significantly
higher han ND mice when considering ses ion 2 (** p < 0.01). Interes ingly, a longer ictal activity
was observed in the KD group in the subsequent sessions of seizure induction. In particular, a statistical
difference was found by comparing session 4 to session 1 in the same animals (# p < 0.05; Holm–Šídák
test). (c) Histograms illustrating the mean duration of post-ictal depression as measured in the various
sessions of 6-Hz corneal stimulation. The duration of post-ictal depression was significantly reduced in
the ND group at the second session of stimulation (## p < 0.01, sessions 2 vs. session 1). Note also that
at the first session, post-ictal depression was shorter in KD mice compared to ND mice (** p < 0.01).
RFC denotes right frontal cortex (epidural electrode). Statistical significance values are indicated as #:
p < 0.05, **: p < 0.01, ##: p < 0.01, ###: p < 0.001.
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Figure 3. Compressed spectral array showing the duration of post-ictal depression in video 
electrocorticographic (ECoG) recordings obtained from mice fed the ketogenic diet (KD) or a normal 
diet (ND) and repeatedly tested in the 6-Hz corneal stimulation model. (a) EcoG traces illustrating 
the response detected in the first session of seizure induction. The white line indicates the duration of 
post-ictal depression. In (b), EcoG traces from mice stimulated in the second session of seizure 
induction. Spectral arrays were from different mice of each respective experimental group. Note that 
the difference observed in the first session is no longer detectable in the second session of 6-Hz 
corneal stimulation. 
Figure 3. Compressed spectral array showing the duration of post-ictal depression in video
electrocorticographic (ECoG) recordings obtained from mice fed the ketogenic diet (KD) or a normal
diet (ND) and repeatedly tested in the 6-Hz corneal stimulation mod l. (a) ECoG traces illustrating
the response de ected in the first sessi n of seizure induc on. The white line indicates th d ration
of post-ictal depression. In (b), ECoG traces from mice stimulated in the second session of seizure
induction. Spectral arrays were from different mice of each respective experimental group. Note that
the difference observed in the first session is no longer detectable in the second session of 6-Hz
corneal stimulation.
2.2. Seizures Worsened in Three Patients Maintained on the KD
The mean age of patients examined in our study was 7.0 ± 0.7 years. Female patients were 71%
(Table 1).
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Table 1. Demographic and clinical features of patients treated with the ketogenic diet (KD). Abbreviations: AEDs, antiepileptic drugs; CBZ, carbamazepine; CLB,
clobazam; CZP, clonazepam; ESM, ethosuximide; GVG, vigabatrin; LEV, levetiracetam; LTG, lamotrigine; NZP, nitrazepam; PB, phenobarbital; PCDC, pyruvate
dehydrogenase complex deficiency; RFN, rufinamide; TPM, topiramate; VPA, valproate; ZNS, zonisamide.
Code Gender Age Diagnosis Type of Seizure AEDs Type of KD Response (Reduction inSeizure Frequency) Transient Side Effects
#1 F 5 Respiratory chain defect I-IIIcomplex Spasm CBZ, NZP, LEV Classic 2:1 88%
Hypercholesterolemia,
hyperoxaluria
#2 F 4 Suspected PDCD Tonic-clonic, spasm NZP, LEV Classic 3:1 92% Nausea, vomiting
#3 F 9.6 Lennox–Gastaut syndrome Spasm, drop attack,tonic-clonic LEV, RFN, NZP Classic 4:1
Transient worsening,
then 78% reduction
Hypertriglyceridemia,
acidosis
#4 F 5 Congenital hydrocephalus Drop attack, myoclonus,absence TPM, LEV Classic 2:1 94% Hypercholesterolemia
#5 M 5.9 Suspect of GLUT1 deficiency Tonic-clonic, spasm TPM, CZP Classic 4:1 52% Hyperphosphatemia
#6 M 5.9 Epileptic encephalopathy Tonic-clonic, spasm GVG, VPA, TPM MCT 3:1 97% No
#7 F 5.4 Partial trisomy forchromosome 13 Tonic-clonic, drop attack VPA, NZP, RFN MCT 3.5:1 96% Nausea, vomiting
#8 M 5.3 Epileptic encephalopathy Tonic-clonic TPM, ESM Classic 3:1 95% No
#9 M 4.7 Suspected GLUT1 deficiency Myoclonus, tonic-clonic GVG, CBZ, NZP Classic 3:1 97% Hypercholesterolemia
#10 M 4 Lissencephaly type 1 Tonic-clonic, spasm CZP, PB, CBZ Classic 4:1 + MCT Worsened Nausea, vomiting
#11 F 3.9 Dravet syndrome Myoclonus TPM, CZP, CLB Classic 2:1 48% No
#12 F 9.3 GLUT1 deficiency Absence, spasm VPA Classic 2.5:1 100% Hypercholesterolemia
#13 M 3 Epileptic encephalopathy Tonic-clonic, drop attack TPM, CZP, CLB Classic 4:1 45% No
#14 F 9.6 Epileptic encephalopathy Absence, spasm VPA, LTG, CLB Classic 4:1 91% Constipation
#15 M 8.2 Suspected PDCD Tremor NZP, LEV Classic 3:1 53% No
#16 F 6 Cerebral cortex malformation Absence, tonic-clonic LEV, LTG MCT 3:1 63% Constipation
#17 F 6.5 West Syndrome Tonic-clonic TAS, CBZ, ESM Classic 2:1 0% No
#18 F 7.1 Lissencephaly type 1 Tonic-clonic, spasm, absence VPA, CLB, RFN Classic 2:1 Worsened No
#19 F 14 Cryptogenic generalizedepilepsy Tonic-clonic, absence LEV, CZP, PB Classic 3:1 73% No
#20 F 14.3 Epileptic encephalopathy Tonic-clonic LEV, ZSN, NZP Classic 4:1 63% Hypercholesterolemia,weight gain
#21 F 10 Epileptic encephalopathy Tonic-clonic, absence LTG, LEV MCT 3:1 51% Vomiting, constipation
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The majority of patients (18/21, 86%) continued the KD for at least 3 months. The KD was started
during hospitalization as a 1:1 ratio and then was progressively increased until an effective level of
ketosis was achieved. All patients developed a ketosis ranging from 2 to 5 mmol/mL during the first
days. Seizures were recorded by parents starting one month in advance and up to 15 weeks after
the KD onset. By excluding patients who stopped the nutritional treatment (cases labeled as #10,
#18, #21 in Table 1), we observed a greater than 50% decrease in the seizure frequency in 15 out of
18 patients (83%) who continued the KD for 3 months, hereafter indicated as responders. In these cases,
a significant relationship was found between ketosis and seizure reduction, as exemplified in Figure 4.
However, in 3 other patients (17%), the decrease in seizure frequency was less than 50%. Finally, in
3 patients (14% of all subjects) seizures worsened under treatment with the KD, but the worsening was
transient in one of these cases.Pharmaceuticals 2017, 10, 82  7 of 14 
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Figure 4. The relationship between ketosis and seizure reduction was analyzed by linear regression in
two patients, whose characteristics are reported in Table 1 (#2 and #6).
Specifically, in one patient, affected by Lennox–Gastaut syndrome associated with tuberous
sclerosis complex, seizures presented with increased severity with no change in the frequency
two weeks from the onset of the nutritional treatment. Then she recovered the therapeutic effect
after an additional two weeks in which no change in the level of ketosis was observed. For this reason,
this patient was nevertheless considered in the long-term as a responder (#3 in Table 1). The aggravation
observed in this case is illustrated by the EEG recordings obtained before the onset of nutritional
treatment (Figure 5a) compared to the EEG recorded after three weeks of KD treatment (Figure 5b),
where it is possible to observe frequent high-voltage spike-waves, especially in the frontal right region,
without a continuous or diffuse pattern and with spike waves that tend to assemble in brief electrical
discharges or in electroclinical crisis. There was no clear explanation for this phenomenon.
In the other two cases, presenting with type I lissencephaly positive to LIS1 mutation, the
aggravation was observed immediately after the KD administration. In these two children we noticed
an increase in seizure frequency (≥25%) already during the first days of treatment (cases #10 and #18,
Table 1). As shown in Figure 6 (only #18 is shown), a clear aggravation of interictal epileptic activity
was detectable by the EEG, where diffuse and high voltage spike-waves appear to be more frequent
without recovering baseline activity. In these cases, seizures were subcontinuously tonic, accompanied
by cyanosis, and alternated with clonic shakes. All these changes disappeared when the KD was
discontinued (not shown).
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treatment with the KD. Note that subcontinuous high-voltage sharp-waves are present (arrowhead), 
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rhythmic eye movements), is also detectable. EEG recordings were made by a 12 channel system 
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Figure 5. The sleep electroencephalogram (EEG) of patient #3 is illustrated. (a) EEG recorded before
starting the ketogenic diet (KD). Note that a lack of spike and wave activities in the centroposterior
areas is indicated by asterisks. Slow and sharp waves are frequently recorded from frontal regions
(arrowheads), with a tendency to generalize and synchronize in bursts. (b) EEG obtained under
treatment with the KD. Note that subcontinuous high-voltage sharp-waves are present (arrowhead),
and that short ictal activity, which corresponded to minimal clinical expression (staring with slow
rhythmic eye movements), is also detectable. E G recordings were made by a 12 chan el system
(Galileo NT Suite Software). I ages r r s t l it i l rea ing ontages. Amplitude,
20 µV/ m.
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Figure 6. The awake electroencephalogram (EEG) of patient #18 is illustrated. (a) EEG before starting 
the ketogenic diet (KD). Note that a short sequence of posterior 5–6 Hz activity is detectable 
(asterisks). Then, this rhythm was interrupted by frequent high-voltage, generalized, and multifocal 
sharp-waves that tended to synchronize in short bursts (arrowheads), followed by a moderate 
reduction of the electrical amplitude. (b) Under treatment with the KD, the presence of continuous, 
high-amplitude, generalized sharp-waves and slow-waves starting from the frontal region is 
appreciable. These waves synchronized in short generalized bursts followed by mild suppression of 
basal activity. Note also that the physiological posterior rhythm was not present. EEG recording was 
made by a 12 channel system (Galileo NT Suite Software). Images are presented on longitudinal 
reading montages. Amplitude, 20 µV/mm. 
Figure 6. The awake electroencephalogram (EEG) of patient #18 is illustrated. (a) EEG before starting
the ketogenic diet (KD). Note that a short sequence of posterior 5–6 Hz activity is detectable (asterisks).
Then, this rhythm was interrupted by frequent high-voltage, generalized, and multifocal sharp-waves
that tended to synchronize in short bursts (arrowheads), followed by a moderate reduction of the
electrical amplitude. (b) Under treatment with the KD, the presence of continuous, high-amplitude,
generalized sharp-waves and slow-waves starting from the frontal region is appreciable. These waves
synchronized in short generalized bursts followed by mild suppression of basal activity. Note also that
the physiological posterior rhythm was not present. EEG recording was made by a 12 channel system
(Galileo NT Suite Software). Images are presented on longitudinal reading montages. Amplitude,
20 µV/mm.
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3. Discussion
In the present investigation, we describe various unreported changes occurring in mice that
are fed with the KD and exposed to repeatedly induced seizures. We also identified three cases
of paradoxically varied epileptic activity in patients affected by drug-resistant seizures and treated
with the KD, in whom seizure frequency and/or severity were increased. To our knowledge, these
clinical findings are also currently unreported. Overall, the major findings of our investigation are:
(i) the prolonged electrographic epileptiform activity found in mice which are fed the KD and which
experience repeated seizures; (ii) the concomitant failure to maintain the therapeutic effects of KD in
the 6-Hz corneal stimulation model; (iii) the lack of any modulatory effect of the KD on epileptogenesis
in our model; iv) the remarkable changes found in the EEG of patients experiencing a progressively
severe clinical condition.
The 6-Hz corneal stimulation model has been suggested to be useful in evaluating the
refractoriness to AEDs [19,28]. This latter is a required condition to propose the KD to patients
affected by epilepsy. Furthermore, the 6-Hz corneal stimulation model was shown to reproduce the
anticonvulsant properties of the KD by demonstrating that the induced ketosis was associated with an
increase in the seizure threshold, or alternatively by showing that key components of the diet could
reproduce the same effects [16,17,29–31]. We challenged the already demonstrated properties of the
KD in our modified 6-Hz corneal stimulation model in which, instead of the threshold, we considered
the severity and duration of the seizure. Surprisingly, we initially observed a beneficial effect of the
KD at the first session of seizure induction. This finding was at odds with previous reports describing
a lack of effects, or even worsening in the response to suprathreshold proconvulsive stimuli in animals
which are fed the KD [14,15]. In all likelihood, differently investigated animal models could explain
these discrepancies.
Rodents exposed to 6-Hz corneal stimulation were never reported to develop spontaneous
seizures, even when daily kindled for weeks by using a more intense stimulation [19] or a higher
frequency [32]. Consistently, our mice did not present seizures in the interstimulation period or after
the four sessions of seizure induction. Thus, our protocol did not induce epilepsy, i.e., a condition
in which unsolicited recurrent seizures can be observed. In particular, as the induced seizures were
worse and worse by repeating the 6-Hz corneal stimulation, our model reproduced some features
typical of the kindling procedure [33], but in presence of a fully effective stimulation. According to
the definition of “secondary epileptogenesis” given to the progression in seizure severity observed
in patients experiencing recurrent seizures [34], we hypothesized that our model could be useful
in addressing the characteristics of seizures refractory to therapeutic treatments. Indeed, we were
surprised to observe that the beneficial effects of the KD subsided at the second seizure induction
and that, paradoxically, the electrographic discharge resulted in approximately double the duration of
values found in control animals. This change accompanied the increased seizure severity observed in
the KD group in the second compared to the first session of 6-Hz corneal stimulation, but no difference
between the two investigated groups was apparent in the duration of both the motor and non-motor
components of the seizure induced by 6-Hz corneal stimulation in the second session [25,28]. Thus,
the prolongation of the electrographic discharge could be a specific feature of seizures resistant to
KD treatment.
We characterized the repeated 6-Hz corneal stimulation model as a paradigm in which some
aspects of epileptogenesis were reproduced. We previously found that a more severe seizure phenotype
appears by repeating the seizure induction, and that this change is associated with the spreading of
the electrographic epileptiform activity to the hippocampal CA1 region [25]. Although we did not
take readings from the hippocampus in the present experiments, we observed that the KD was not
able to prevent the appearance of more severe seizures in mice exposed to repeated 6-Hz corneal
stimulation. So, the KD failed in exerting an antiepileptogenic effect in our model. This interpretation
is supported by previous results obtained in mice treated with the anticonvulsant peptide EP-80317,
which was instead able to delay the appearance of more severe seizures up to the third session of
Pharmaceuticals 2017, 10, 82 11 of 15
corneal stimulation [26]. Of course, the negative findings obtained in the 6-Hz model do not exclude
the possibility that other antiepileptogenic effects could be revealed in different models. Indeed,
the KD was shown to be effective by using both electrical and chemical kindling procedures, as well as
in the pilocarpine model [21,22]. On the other hand, lack of efficacy or partially beneficial effects were
also reported for the KD, respectively, in the lithium-pilocarpine model [24] or in genetically epileptic
mice [23], thus suggesting a strong influence of the investigated animal model on the efficacy of KD
administration on epileptogenesis.
In three patients, we observed a paradoxical effect of the KD. This phenomenon resembles that
described for AEDs [10]. Since we carefully monitored the ketosis induced by the KD, the observed
worsening was unexpected. Blood levels of AEDs were also carefully monitored in our patients, and
no additional complications were recorded. Thus, there was no clear explanation for the paradoxical
response observed in the three patients treated with the KD. However, in one of them affected by the
Lennox–Gastaut syndrome the aggravation was only transient and did not prevent the continuation of
the treatment. On the contrary, the KD had to be stopped in the two patients affected by lissencephaly.
We considered the possibility that the presence of this specific disease could be a reason for the
worsening. However, patients affected by the same condition were successfully treated with the
KD by other investigators [35]. The analogue paradoxical responses reported for AEDs were also
without a clear explanation, as in the case of our patients, and they were generally interpreted as an
adverse reaction to the mechanism of the prescribed AED, occurring only in some patients [10]. Indeed,
further investigations are required to understand the reasons why the KD might cause a paradoxical
worsening. To this aim, the 6-Hz model of repeated corneal stimulation may provide an experimental
tool to give these answers.
4. Materials and Methods
A total of 18 (four week-old) male CD-1 mice (Charles River, Calco, Italy) were used in this study.
They were housed in a specific pathogen-free facility under a controlled environment with ad libitum
access to water and food. Mice were randomly assigned to two distinct treatment groups. Of these
mice, nine were fed the ND. Nine mice, instead, received the KD for two weeks (Teklad TD.96355,
Harlan Italy) before being subjected to the 6-Hz corneal stimulation test (Figure 7). The KD was also
administered during the testing period and consisted of (g%, w/w) 67.43 fats, 15.08 proteins, and
0.54 carbohydrates, resulting in a fats-to-proteins+carbohydrates ratio of 4.3:1. The caloric density of
the KD was 6.69 kcal g−1 (fats: 90.66%; proteins: 9.01%; carbohydrates: 0.32%). Mice were weighed
once a week to monitor body growth.
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Figure 7. Timeline of the experiment with mice aintained on the normal diet (ND) or on the ketogenic
diet (KD) and exposed to various sessions of 6-Hz corneal stimulation.
For electrode implantation, mice were anesthetized with ketamine + xylazine (150 + 10 µg/g).
Guiding holes were drilled and epidural electrodes (stainless steel Ø = 1 mm; PlasticsOne, Roanoke,
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VA, USA) were implanted in the frontal (bregma 0 mm, 3 mm lateral from midline) and occipital
cortices (bregma −3.5 mm, 3 mm lateral from midline) of the right hemisphere [25–27]. One electrode
was implanted below lambda on the midline and used as reference. At the end of the surgery, gel
containing 2.5 g lidocaine chloride, 0.5 g neomycin sulfate and 0.025 g fluocinolone acetonide (Neuflan®
gel; Molteni Farmaceutici, Florence, FI, Italy) was applied to reduce pain and the risk of infection.
Mice were placed in cages without a cover to allow a cable to connect the headset and
preamplifiers. Electrical brain activity was filtered (0.3 Hz high-pass, 500 Hz low-pass), acquired at
1 kHz per channel, and stored on a personal computer as the mathematical subtraction of traces
of recording electrodes minus traces of reference electrode (only for epidural electrodes), using
a PowerLab8/30 amplifier connected to four BioAmp preamplifiers (ADInstruments, Dunedin,
New Zealand). Videos were digitally captured by a camera connected to the computer and
synchronized to the ECoG traces by LabChart 7 Pro internal trigger.
Mice were stimulated once and let to recover for three days before being stimulated for a
second time. Corneal stimulation was as previously described [25–27]. Briefly, ocular anesthetic
(0.4% oxybuprocaine hydrochloride eye drops, Novesin, Laboratoires Théa, 63000 Clermont-Ferrand,
France) was applied 10 min before stimulation. Stimulation (fixed current intensity of 32 mA, pulse
width of 0.2 msec, duration of 3 sec, frequency of 6 Hz) was delivered via external non-invasive
corneal electrodes connected to a stimulator (ECT Unit 5780; Ugo Basile, Comerio, Italy), as shown by
Castel-Branco et al. [36].
All experiments were in compliance with the European Directive 2010/63/EU and carried out
according to the national guidelines on animal experimental research of the Italian Ministry of Health
(DM 92/2013). The University of Modena and Reggio Emilia Ethics Committee approved the study
protocol. All efforts were made to refine procedures to improve the welfare and to reduce the number
of animals that were used.
ECoG traces were offline digitally filtered (band-pass: high 50 Hz, low 1 Hz) and manually
analyzed using LabChart 7 Pro software v7.3.8 (ADInstruments) by blind to treatment expert raters.
Seizures were characterized by epileptiform ECoG patterns occurring right after the stimulus artifact.
ECoG patterns characterized by trains of 150–250 ms long spikes with amplitudes at least twice as the
previous 2 sec baseline were considered as electrographic seizures.
Patients with drug-resistant seizures admitted to the pediatric neurology service between
April 2011 and February 2017 and treated with the KD were retrospectively examined. These patients
were treated with the KD due to (i) a failure of drug treatment with two or more appropriately chosen
AEDs; (ii) good compliance with AED administration; (iii) lack of alterations of serum amino acids,
urine organic acids, acylcarnitine, lactate, pyruvate, and ammonia blood levels. They received the
nutritional treatment by starting with a 2:1 ratio of lipids and proteins + carbohydrates and, after
few days, shifting to a 3.5/4:1 ratio [37]. Routine laboratory and encephalographic investigations were
fully available for at least 1–3 months of treatment. Blood levels of AEDs were also recorded. The final
study was conducted on a cohort of 21 subjects with ages ranging from 3 to 15 years. Data about
demographic features, clinical characteristics, diagnostic findings, therapeutic interventions, and
clinical outcomes are reported in Table 1.
The ketone body β-hydroxybutyric acid was measured in fasting blood samples obtained by
isoflurane anesthetized mice, one day after the testing procedure. Precisely, trunk blood was collected
after decapitation of deeply anesthetized mice. One drop of blood was adsorbed on a test strip and
read with the Precision Xtra Blood Ketone Meter (Abbott Diabetes Care, Rome, Italy). In patients,
fasting glucose and ketone basal values were noted during hospitalization; after that, parents reported
glycaemia and β-hydroxybutyric acid levels three times/day/week up to 15 weeks.
β-hydroxybutyric acid levels were compared by Student’s t test. Linear regression analysis was
applied to investigate the relationship between ketosis and seizure reduction. Fisher’s exact test was
used to compare mice that developed seizures with loss of posture with those that maintained posture
control, in the two different groups of treatment. Seizure duration and electrographic recordings were
Pharmaceuticals 2017, 10, 82 13 of 15
compared using two-way analysis of variance, considering the different diet as the between factor
and the session of 6-Hz corneal stimulation as the within factor. The Holm–Šídák test was used for
multiple comparisons. All statistical analyses were carried out using Sigmaplot 11 (Systat Software,
San Jose, CA, USA). Data are presented as mean± standard error of the mean (SEM) and were regarded
significantly different at p < 0.05.
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